Diabetic and Non-Diabetic Gastroparesis: A Retrospective Comparative Outcome Study From the Nationwide Inpatient Sample.
Complications
Diabetic gastroparesis
Mean length of stay
Mortality
Nationwide inpatient sample
Non-diabetic gastroparesis
Outcome
Total hospital cost
Journal
Gastroenterology research
ISSN: 1918-2805
Titre abrégé: Gastroenterology Res
Pays: Canada
ID NLM: 101519422
Informations de publication
Date de publication:
Feb 2021
Feb 2021
Historique:
received:
17
01
2021
accepted:
11
02
2021
entrez:
19
3
2021
pubmed:
20
3
2021
medline:
20
3
2021
Statut:
ppublish
Résumé
Gastroparesis (GP), meaning "gastric palsy", is a chronic medical condition characterized by delayed or absent gastric emptying in the absence of mechanical obstruction. The primary objective of this study was to determine the patient-specific outcomes and the burden of GP on the US healthcare system. This was a population-based, retrospective study designed to analyze data available from the Nationwide Inpatient Sample (NIS) for 2016 and 2017. Using the International Classification of Diseases, Tenth Revision (ICD-10) codes, we identified adult (18 years or older) hospitalizations with a principal diagnosis of GP. The study sample was further classified into two distinct groups based on the presence or absence of GP, namely diabetic GP (DGP) and non-diabetic GP (NDGP). The primary outcome of our study was inpatient mortality secondary to GP while the secondary outcomes included the odds of system-based complications and the burden of the disease on the United States healthcare system. We identified 99,695 adult (≥ 18 years) hospitalizations with a principal discharge diagnosis of GP in 2016 and 2017. Of these patients, 78.1% (77,885) had DGP and 21.9% (21,810) were classified in the NDGP group. We noted a higher proportion of women (79.3% vs. 63.4%, P < 0.001), patients with a history of smoking (35.8% vs. 31.7%, P < 0.001) and chronic obstructive pulmonary disease (10.7% vs. 7.6%, P < 0.001) in the NDGP group. After adjusting for common confounders excluding age, the inpatient mortality for GP was found to be 0.25%. Furthermore, after adjustments were made for the Charlson comorbidity index (CCI), we noted higher odds of mortality in the NDGP group (0.30% vs. 0.23%, adjusted odds ratio (aOR): 3.18, 95% confidence interval (CI): 1.75 - 5.79, P < 0.001) compared to the DGP group. Additionally, patients with NDGP had a higher mean length of stay (5 vs. 4.1 days, P < 0.001) and higher mean total hospital charge ($44,100 vs. $35,500, P < 0.001) compared to those with DGP. The NDGP group also had higher odds of sepsis, deep vein thrombosis (DVT) and pulmonary embolism (PE); however, the odds of developing acute kidney injury (AKI) were lower than that of the DGP group. The inpatient mortality for GP was found to be 0.25%. After adjusting for CCI, patients with NDGP had higher odds of inpatient mortality compared to the DGP group. Additionally, patients with NDGP were associated with a longer length of hospital stay, mean total healthcare cost and higher odds of complications such as sepsis, DVT and PE during the hospitalization.
Sections du résumé
BACKGROUND
BACKGROUND
Gastroparesis (GP), meaning "gastric palsy", is a chronic medical condition characterized by delayed or absent gastric emptying in the absence of mechanical obstruction. The primary objective of this study was to determine the patient-specific outcomes and the burden of GP on the US healthcare system.
METHODS
METHODS
This was a population-based, retrospective study designed to analyze data available from the Nationwide Inpatient Sample (NIS) for 2016 and 2017. Using the International Classification of Diseases, Tenth Revision (ICD-10) codes, we identified adult (18 years or older) hospitalizations with a principal diagnosis of GP. The study sample was further classified into two distinct groups based on the presence or absence of GP, namely diabetic GP (DGP) and non-diabetic GP (NDGP). The primary outcome of our study was inpatient mortality secondary to GP while the secondary outcomes included the odds of system-based complications and the burden of the disease on the United States healthcare system.
RESULTS
RESULTS
We identified 99,695 adult (≥ 18 years) hospitalizations with a principal discharge diagnosis of GP in 2016 and 2017. Of these patients, 78.1% (77,885) had DGP and 21.9% (21,810) were classified in the NDGP group. We noted a higher proportion of women (79.3% vs. 63.4%, P < 0.001), patients with a history of smoking (35.8% vs. 31.7%, P < 0.001) and chronic obstructive pulmonary disease (10.7% vs. 7.6%, P < 0.001) in the NDGP group. After adjusting for common confounders excluding age, the inpatient mortality for GP was found to be 0.25%. Furthermore, after adjustments were made for the Charlson comorbidity index (CCI), we noted higher odds of mortality in the NDGP group (0.30% vs. 0.23%, adjusted odds ratio (aOR): 3.18, 95% confidence interval (CI): 1.75 - 5.79, P < 0.001) compared to the DGP group. Additionally, patients with NDGP had a higher mean length of stay (5 vs. 4.1 days, P < 0.001) and higher mean total hospital charge ($44,100 vs. $35,500, P < 0.001) compared to those with DGP. The NDGP group also had higher odds of sepsis, deep vein thrombosis (DVT) and pulmonary embolism (PE); however, the odds of developing acute kidney injury (AKI) were lower than that of the DGP group.
CONCLUSIONS
CONCLUSIONS
The inpatient mortality for GP was found to be 0.25%. After adjusting for CCI, patients with NDGP had higher odds of inpatient mortality compared to the DGP group. Additionally, patients with NDGP were associated with a longer length of hospital stay, mean total healthcare cost and higher odds of complications such as sepsis, DVT and PE during the hospitalization.
Identifiants
pubmed: 33737996
doi: 10.14740/gr1364
pmc: PMC7935612
doi:
Types de publication
Journal Article
Langues
eng
Pagination
21-30Informations de copyright
Copyright 2021, Kichloo et al.
Déclaration de conflit d'intérêts
The authors report no conflict of interest.
Références
Medscape J Med. 2008 Jan 23;10(1):16
pubmed: 18324326
Dig Dis Sci. 2017 Apr;62(4):879-893
pubmed: 28110376
Gastroenterol Hepatol (N Y). 2010 Jun;6(6):1-16
pubmed: 20733935
Dig Dis Sci. 1998 Sep;43(9):1951-6
pubmed: 9753257
Gastroenterol Clin North Am. 2015 Mar;44(1):69-81
pubmed: 25667024
J Pediatr. 1997 Nov;131(5):751-4
pubmed: 9403659
World J Gastroenterol. 2016 Jul 7;22(25):5742-52
pubmed: 27433087
Gastroenterology. 2009 Apr;136(4):1225-33
pubmed: 19249393
Open Forum Infect Dis. 2015 Jul 08;2(3):ofv103
pubmed: 26269797
Gastroenterology Res. 2018 Oct;11(5):340-345
pubmed: 30344804
Clin Gastroenterol Hepatol. 2011 Dec;9(12):1056-64; quiz e133-4
pubmed: 21871247
Clin Investig. 1992 Jun;70(6):487-91
pubmed: 1392416
J Child Neurol. 2013 Dec;28(12):1716-9
pubmed: 23358630
Diabetes. 2007 May;56(5):1475-80
pubmed: 17303799
Am J Gastroenterol. 2013 Jan;108(1):18-37; quiz 38
pubmed: 23147521
Scientifica (Cairo). 2012;2012:424802
pubmed: 24278691
Gut Liver. 2017 Sep 15;11(5):579-589
pubmed: 28535580
Aliment Pharmacol Ther. 2008 Jan 15;27(2):186-96
pubmed: 17973643
Gastrointest Endosc. 1998 Jan;47(1):67-70
pubmed: 9468426
Nat Rev Dis Primers. 2018 Nov 1;4(1):41
pubmed: 30385743
J Altern Complement Med. 2008 Sep;14(7):833-9
pubmed: 18721079
Neurogastroenterol Motil. 2006 Apr;18(4):263-83
pubmed: 16553582
Klin Med (Mosk). 1951 Mar;29(3):35-41
pubmed: 14825652
Neurogastroenterol Motil. 2006 Feb;18(2):162-7
pubmed: 16420295
Gut. 2019 Dec;68(12):2238-2250
pubmed: 31563877
Gastroenterol Clin North Am. 2015 Mar;44(1):59-68
pubmed: 25667023
Am J Gastroenterol. 1998 Jul;93(7):1085-9
pubmed: 9672335
Gastrointest Endosc. 2011 Sep;74(3):496-503.e3
pubmed: 21872708
Dig Dis Sci. 1992 Oct;37(10):1544-7
pubmed: 1396001
Clin Gastroenterol Hepatol. 2008 Jun;6(6):635-643.e1
pubmed: 18406670
Dig Dis Sci. 2002 May;47(5):1020-6
pubmed: 12018897
Diabetes Ther. 2018 Jul;9(Suppl 1):1-42
pubmed: 29934758
J Clin Gastroenterol. 2019 Feb;53(2):109-113
pubmed: 29256990
Results Immunol. 2016 Mar 03;6:11-4
pubmed: 27014566
Am J Gastroenterol. 1999 Apr;94(4):1029-33
pubmed: 10201478
Clin Gastroenterol Hepatol. 2008 Sep;6(9):988-92
pubmed: 18599359
Curr Gastroenterol Rep. 2007 Aug;9(4):280-5
pubmed: 17883974
Gastroenterol Clin North Am. 2015 Mar;44(1):9-19
pubmed: 25667019
J Neurogastroenterol Motil. 2012 Jan;18(1):34-42
pubmed: 22323986
Clin Rev Allergy Immunol. 2005 Dec;29(3):255-69
pubmed: 16391401
Diabetes. 2013 Aug;62(8):2667-73
pubmed: 23881199
J Patient Cent Res Rev. 2019 Apr 29;6(2):133-134
pubmed: 31414024
Dig Dis Sci. 1999 Jun;44(6):1061-75
pubmed: 10389675
Gut. 2014 Dec;63(12):1972-8
pubmed: 25260920
Diabetes Care. 2010 Jan;33 Suppl 1:S62-9
pubmed: 20042775
Ann Intern Med. 1980 Mar;92(3):370-3
pubmed: 6766695
Am J Gastroenterol. 2008 Mar;103(3):753-63
pubmed: 18028513
Gastroenterology. 2011 Aug;141(2):486-98, 498.e1-7
pubmed: 21684286
World J Gastroenterol. 2020 May 21;26(19):2333-2348
pubmed: 32476797
Curr Diab Rep. 2013 Dec;13(6):814-23
pubmed: 24037313
Gastroenterology. 1991 Jan;100(1):252-8
pubmed: 1983829
World J Gastroenterol. 2017 Jun 28;23(24):4428-4436
pubmed: 28706426
Nat Clin Pract Gastroenterol Hepatol. 2007 Jun;4(6):336-46
pubmed: 17541447
Am J Gastroenterol. 2011 Aug;106(8):1492-502
pubmed: 21483459
Am J Case Rep. 2015 Nov 10;16:801-4
pubmed: 26552851
J Gastroenterol Hepatol. 2007 Sep;22(9):1423-8
pubmed: 17716347